STHREE is a world leader in the recruitment industry, boasting a unique portfolio of renowned recruitment brands and job boards. The company price shows a bullish trend since a long time.
Fundamental analysis reveals a healthy stock which earnings should increase more than double from 2013 to 2014. This positive trend is confirmed by “Surperformance” rating for investments and trading.
This company has been experiencing a well-oriented path since the last seven sessions and this direction should continue on the following trading days. Even if part of the gain has been guzzled it still remains a lot of opportunities for new trading on the stock. If the price arises over the pivot point at GBp 391 (and the trendline) on today’s session, this situation will enable investors to take advantage from a prolongation of the bullish path. Furthermore, a valuable indicator for a pursuing are the 20 and 50-day moving average that show a rising slope.
For reasons exposed above, investors should buy the stock if the pivot point at GBp 391 is broke up. The target is towards GBp 434 with a stop loss placed under GBp 375.
SThree plc is a United Kingdom-based global specialist talent partner focused on roles in Science, Technology, Engineering and Mathematics, providing permanent and flexible contract talent. Its segments include DACH, Rest of Europe, Netherlands including Spain, USA, and Middle East & Asia. DACH segment includes Austria, Germany and Switzerland. Rest of Europe segment includes Belgium, France and the United Kingdom. Middle East & Asia segment includes Dubai and Japan. Its brands include Progressive Recruitment, Computer Futures, Real Staffing and Huxley. Progressive Recruitment is involved in start-up and blue-chip multinational sectors, providing sought-after specialists in engineering, life sciences, information technology, global energy, construction and supply chains. Computer Futures is a specialist IT recruitment provider. Real Staffing is engaged in recruitment for the pharmaceuticals, medical devices and biotechnology sectors, with specialist services within the public sector.